- By Deepti Babu, MS, CGC
- Posted April 3, 2017
Current Genetic Testing Guidelines Miss Some Families with CDH1 Mutations
Hereditary diffuse gastric cancer (HDGC) is an inherited cancer syndrome caused by CDH1 gene mutations. It occurs most frequently in Japan and eastern Asia; current incidence in the U.S. is estimated at 10-40 individuals per 100,000.1 Individuals with mutations in the CDH1 gene have up to an 80% lifetime risk of diffuse gastric…
- By Jackie Connor
- Posted March 31, 2017
Ambry Experts Provide Insight on Genetic Testing’s Clinical Utility at the 2017 SSO Annual Cancer Symposium
Ambry has continued to provide clinicians with the most relevant and useful information to encourage education about the benefits of genetic testing for patients and ways to streamline genetic testing in clinical practice. At the 2017 SSO Annual Cancer Symposium, Ambry hosted the presentation “On the Cutting Edge: Sharpening Your Genetic Awareness…
- By Jackie Connor
- Posted March 30, 2017
Ambry Talks Plans for Personalized Genomic Test Launch, Third Annual Trivia Night a Hit
On Thursday evening, March 23rd, an audience of more than 100 genetic counselors and geneticists from across the United States listened to Ambry Genetics’ Clinical Genomics Marketing Manager Layla Shahmirzadi, MS, CGC, discuss plans to launch a personalized genomic test for healthy individuals. The talk took place at Events on Jackson venue…
- By Jackie Connor
- Posted March 30, 2017
Dr. Rachid Karam Discusses Variant Classification at 2017 ACMG Annual Meeting
Actionable medical results are often a key component in deciding a patient’s medical management and specialized treatment options. However, some genetic test results can have unclear implications or Variants of Unknown Significance (VUS), which can often affect a clinician’s medical management plans for their patients. During the 2017 ACMG…
- By Jackie Connor
- Posted March 21, 2017
Recapping Ambry at the 2017 Annual Meeting on Women’s Cancer
Ambry experts and collaborators presented new research at this year’s Annual Meeting on Women’s Cancer. In addition to discussing GYNplus and OvaNext testing options, Ambry featured three scientific posters and a lunch presentation “Advancing Molecular Diagnostics for Gynecologic Cancer: Efforts in Data Sharing and Tumor Testing to Improve…
- By Jackie Connor
- Posted March 14, 2017
Four Reasons Why Genetic Testing Matters to the Individual with Colorectal Cancer
Colon cancer is the third most common cancer diagnosed in both men and women in the United States, and more than 95,000 new cases of colon cancer and 39,000 new cases of rectal cancer are estimated for 2017, according to the American Cancer Society. Up to 10% of colorectal cancer is hereditary, or caused by inherited gene mutations. Hereditary…
- By Jackie Connor
- Posted March 2, 2017
RNA Labs—How they Impact the Medical World
Ribonucleic Acid, otherwise known as RNA, is the messenger that carries instructions for controlling the synthesis of proteins from Deoxyribonucleic Acid (DNA). The central dogma of molecular biology states that “DNA makes RNA makes protein." However, for the proteins, which are the final product, to work properly, the RNA needs to be “edited,"…
- By Jackie Connor
- Posted February 16, 2017
Scientific Research Consent Made Easy
Since March 2016, Ambry has been collecting data samples from researchers through the data sharing program AmbryShare, with a goal of improving scientific research aimed at making more tailored treatments and/or cures available to clinicians and their patients. Now anyone can participate in a research study and choose to either submit an e-consent…
- By Jackie Connor
- Posted February 6, 2017
Genetic Testing Accuracy Explained During the AmbrySpeaks-Los Angeles Event
In the first of seven dinner series events, on Tuesday, January 31st, Ambry Genetics presented to more than 45 attendees at Spago in Beverly Hills, California. The “AmbrySpeaks Tour—Accuracy and Innovation in the Era of Collaborative Genetics” challenges the common misconception that Next-generation sequencing (NGS) is 100 percent accurate,…
- By Deepti Babu, MS, CGC
- Posted February 2, 2017
Exome Sequencing Provides More Coverage Than You Think
Advances in molecular diagnostics offer clinicians more choices than ever when it comes to disease-targeted genetic testing for their patients.1 However, the amount of options can complicate deciding which test is best for each patient. Next generation sequencing (NGS)-based clinical genetic tests, such as multi-gene panel testing (MGPT), offer…